What is it about?

• Addressing theories of liability implicating managed care organizations in the current opiod litigation
• Risk management perspective: how are MCOs handling opioid procedures internally?
• Addressing treatment for addiction not typically covered: How have plans evolved, if at all, as a result of the epidemic?
  • What changes are plans seeing in their policies in relation to opioid therapies and treatments?
• Exploring the interest in recouping funds from prescribers who are overprescribing
• Examining the possibility and probability of suing opioid manufacturers
  • Examining potential affirmative claims health plans would be bringing against manufacturers, distributors, and providers